RBCC Partner n3D Explores New Business Opportunities at Biomedical Conference

NOKOMIS, Fla.--(BUSINESS WIRE)-- Rainbow BioSciences, LLC, the biotech subsidiary of Rainbow Coral Corp. (OTCBB:RBCC), announced today that its newest partner, Nano3D Biosciences (n3D), introduced its cell-levitation technology to dozens of potential clients this week at the 28th Southern Biomedical Engineering Conference in Houston.

By targeting the top industry professionals, n3D is successfully generating increased awareness and interest surrounding the Bio-Assembler. The system’s revolutionary functionality allows it to produce accurate, 3D representations of in vivo tissues in roughly the same time needed to produce 2D cell cultures.

The conference brought together students, researchers, clinicians and industry leaders in various fields of biomedical engineering, other engineering disciplines and medicine to share the latest tools and techniques in the rapidly growing sector. This event was particularly targeted toward medical oncologists and hematologists, corporate medical directors and health plan medical directors and other healthcare professionals.

Nano3D Biosciences’s 3D cell culturing system, the Bio-Assembler, was featured in a number of abstracts presented at the conference. This gave the company an opportunity to help familiarize students and professionals on the cutting edge of biomedical breakthroughs and research to its innovative technology.

With n3D’s Bio-Assembler poised to dramatically reduce the development timeline for new life-saving drug therapies, Rainbow BioSciences acquired an equity interest in n3D earlier this year. RBCC believes that this acquisition has the company well-positioned to participate in the potentially impressive upside in store for n3D.

For more information on Rainbow BioSciences, please visit www.rainbowbiosciences.com/investors.html.

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen, Inc. (NASDAQ: AMGN).

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.



CONTACT:

Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO
[email protected]

KEYWORDS:   United States  North America  Florida  Texas

INDUSTRY KEYWORDS:   Technology  Nanotechnology  Health  Biotechnology

MEDIA:

Suggested Articles

Healthcare software company Phreesia closed its first day of trading as a public company Thursday about 40% above its set price.

The announcement comes on the heels of the Trump administration's effort aimed at kidney care that includes expanding access to in-home dialysis.

Technology company Philips has acquired Boston-based startup Medumo, the developer of patient navigation and engagement solutions.